436.00
Vertex Pharmaceuticals Inc stock is traded at $436.00, with a volume of 1.43M.
It is up +0.45% in the last 24 hours and down -11.46% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$434.03
Open:
$428.68
24h Volume:
1.43M
Relative Volume:
0.86
Market Cap:
$111.96B
Revenue:
$11.10B
Net Income/Loss:
$-988.90M
P/E Ratio:
-111.22
EPS:
-3.92
Net Cash Flow:
$-1.26B
1W Performance:
-0.60%
1M Performance:
-11.46%
6M Performance:
-3.32%
1Y Performance:
-3.28%
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
Nov-14-24 | Initiated | Citigroup | Buy |
Oct-16-24 | Initiated | Scotiabank | Sector Perform |
Oct-10-24 | Resumed | Raymond James | Mkt Perform |
Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
Jun-27-24 | Initiated | Redburn Atlantic | Buy |
Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
May-30-23 | Initiated | William Blair | Outperform |
May-04-23 | Resumed | Piper Sandler | Overweight |
Mar-21-23 | Initiated | Bernstein | Outperform |
Jan-18-23 | Initiated | Canaccord Genuity | Hold |
Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
May-23-22 | Initiated | SVB Leerink | Mkt Perform |
May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jan-27-22 | Reiterated | JP Morgan | Overweight |
Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
Jan-27-22 | Reiterated | Stifel | Hold |
Jan-27-22 | Reiterated | Wolfe Research | Outperform |
Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Dec-09-21 | Initiated | Wells Fargo | Overweight |
Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Sep-09-21 | Downgrade | Stifel | Buy → Hold |
Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
Jul-19-21 | Resumed | Wolfe Research | Outperform |
Jul-01-21 | Initiated | Raymond James | Mkt Perform |
Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
Dec-30-20 | Initiated | Daiwa Securities | Outperform |
Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-20-20 | Initiated | Bernstein | Outperform |
Oct-28-20 | Initiated | UBS | Buy |
Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Mar-04-20 | Initiated | Barclays | Overweight |
Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
Nov-12-19 | Initiated | SunTrust | Buy |
Oct-17-19 | Resumed | BofA/Merrill | Buy |
Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
Aug-01-19 | Downgrade | Needham | Buy → Hold |
May-23-19 | Resumed | Citigroup | Buy |
May-21-19 | Initiated | Credit Suisse | Outperform |
Apr-12-19 | Initiated | Evercore ISI | In-line |
Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
2 Monster Growth Stocks to Buy and Hold for 10 Years - The Motley Fool
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline? (NASDAQ:VRTX) - Seeking Alpha
Argus Adjusts Price Target on Vertex Pharmaceuticals to $525 From $550 - marketscreener.com
Vertex Pharmaceuticals (VRTX) Downgraded Due to High Inventory Levels | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals (VRTX) Announces $4 Billion Share Buyback Program - GuruFocus
Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN
Vertex Pharma announces new share buybacks worth up to $4B - MSN
Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 - Yahoo Finance
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Benzinga
Vertex Pharma stock gains on share buybacks (VRTX:NASDAQ) - Seeking Alpha
Vertex Pharmaceuticals (VRTX) Announces New $4 Billion Stock Rep - GuruFocus
Vertex Pharmaceuticals Authorizes $4 Billion In Additional Share Repurchases - marketscreener.com
August 15th Options Now Available For Vertex Pharmaceuticals (VRTX) - Nasdaq
VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss - Yahoo Finance
Vertex to Participate in Upcoming Investor Conferences | VRTX Stock News - GuruFocus
Vertex to Participate in Upcoming Investor Conferences - Business Wire
Vertex Pharmaceuticals Holds Annual Shareholder Meeting - TipRanks
Stifel maintains hold on Vertex stock with $494 target - Investing.com
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
Best Biotech Stocks to Buy in 2025 - MarketBeat
Fund Update: TRILLIUM ASSET MANAGEMENT, LLC added 38,854 shares of VERTEX PHARMACEUTICALS ($VRTX) to their portfolio - Nasdaq
Our future journey in cystic fibrosis - Vertex Pharmaceuticals
Vertex says late-stage studies of VX-659 triple combination therapy in CF hit main goals - FirstWord Pharma
ViewPoints: Vertex settles on a dynastic successor - FirstWord Pharma
Vertex's VX-445 triple combination regimen achieves main goals of two late-stage studies in CF - FirstWord Pharma
Vertex moves forward with regulatory filings after selecting VX-445 for triple-combination regimen in CF - FirstWord Pharma
Is Vertex Pharmaceuticals (VRTX) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? - Benzinga
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - MSN
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft - CNBC
Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment - Insider Monkey
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Incorporated Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks - MSN
Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss - MSN
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Vertex Says 20,000 Prescriptions Filled for Non-Opioid Pain Drug - MSN
Leerink Partners Downgrades Vertex Pharmaceuticals (XTRA:VX1) - Nasdaq
Vertex Pharmaceuticals (VRTX) Faces Downgrade After Q1 Revenue Miss - GuruFocus
Vertex Pharma stock downgraded at Wolfe (VRTX:NASDAQ) - Seeking Alpha
Cystic fibrosis Market: Epidemiology, Therapies, Companies, - openPR.com
Leerink Partners Downgrades Vertex Pharmaceuticals (BIT:1VRTX) - Nasdaq
Vertex Pharmaceuticals (VRTX) Sees Target Price Increase to $499 by Barclays | VRTX Stock News - GuruFocus
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - AOL.com
Leerink Partners Downgrades Vertex Pharmaceuticals (WBAG:VRTX) - Nasdaq
Wolfe Research Downgrades Vertex Pharmaceuticals to Peer Perform From Outperform - marketscreener.com
Vertex Pharmaceuticals (VRTX) Downgraded Amid Revenue Concerns | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):